The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating the virulent Bundibugyo ebolavirus (BDBV) epidemic currently afflicting regions within the Democratic Republic of the Congo (DRC) and Uganda. This critical move, following a rigorous global review and extensive consultations with leading health authorities including the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC), underscores the escalating concern over a pathogen for which no licensed vaccines or treatments currently exist. The selected candidates, originating from the International AIDS Vaccine Initiative (IAVI), Moderna, and the University of Oxford, represent a multi-platform scientific assault on a rare yet deadly form of Ebola, highlighting a proactive global health security strategy.
Understanding the Bundibugyo Threat
The Bundibugyo ebolavirus is one of six known species of Ebolavirus, a genus within the family Filoviridae. While less frequently encountered than the Zaire ebolavirus, which caused the devastating West Africa epidemic of 2014-2016 and numerous outbreaks in the DRC, BDBV is equally lethal, with case fatality rates estimated to be up to 50%. Its rarity has historically meant that pharmaceutical development has not prioritized BDBV-specific interventions, leaving affected communities vulnerable. Prior to the current situation, there had only been two documented outbreaks caused by BDBV: the first in 2007 in Bundibugyo District, Uganda, and a subsequent smaller event. The current epidemic in the DRC and Uganda, therefore, represents a significant public health challenge, requiring an immediate and coordinated response. The geographical proximity and porous borders between the affected regions in the DRC and Uganda further complicate containment efforts, increasing the risk of wider regional spread.
The broader context of Ebola outbreaks in Central and East Africa highlights the persistent threat. The region has grappled with numerous outbreaks over decades, straining already fragile healthcare systems and fostering community mistrust in external health interventions. The Zaire ebolavirus vaccine, Ervebo, proved highly effective in curbing the 2018-2020 outbreak in eastern DRC, demonstrating the transformative power of rapid vaccine deployment during an epidemic. However, the lack of a similar tool for BDBV leaves a dangerous gap in preparedness.
CEPI’s Proactive Stance on Epidemic Preparedness
CEPI, established in 2017 in response to the lessons learned from the 2014-2016 West Africa Ebola crisis, plays a pivotal role in accelerating the development of vaccines against emerging infectious diseases. Its mission is to prevent future epidemics by funding and coordinating research and development for pathogens that pose a significant public health threat but may lack commercial incentive for private sector investment. This "market failure" often leaves populations at risk, particularly in low- and middle-income countries. CEPI’s strategy involves investing in promising vaccine candidates for priority pathogens, known as "Disease X," to ensure that effective countermeasures are available or rapidly deployable when new outbreaks occur.
Richard Hatchett, CEO of CEPI, articulated the urgency behind the organization’s decision. "With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," Hatchett stated in a press release. He emphasized that "CEPI’s urgent funding and support for these three promising candidates aims to advance safe, effective vaccines to help control this epidemic." This statement underscores CEPI’s foundational principle: to accelerate vaccine development to outpace the spread of infectious diseases. The selection of these three candidates, following a thorough assessment of preclinical data, manufacturing feasibility, and platform adaptability, reflects a strategic approach to maximize the chances of success against a formidable foe.
The Frontrunners: A Trio of Promising Technologies
The three vaccine candidates represent diverse and advanced technological approaches, each bringing unique advantages to the fight against BDBV.
1. IAVI’s rVSV Vaccine: Building on Proven Success
The candidate from IAVI utilizes a recombinant vesicular stomatitis virus (rVSV) platform, a technology that has already demonstrated significant success in the fight against Ebola. Originally developed at The University of Texas Medical Branch, this rVSV-based vaccine is designed to elicit protective immunity after a single dose. Its greatest strength lies in its proven track record: it is the same technology employed in the only currently licensed Zaire ebolavirus vaccine, Ervebo (VSV-ZEBOV), which was instrumental in controlling the 2018-2020 outbreak in the DRC. Furthermore, a similar rVSV platform was successfully deployed during a 2025 Sudan virus outbreak in Uganda, showcasing its adaptability across different Ebolavirus species.
While this specific BDBV candidate has demonstrated protective efficacy in non-human primate studies, it has not yet undergone evaluation in human clinical trials. However, the WHO identified it as the most promising vaccine candidate among those selected by CEPI, likely due to the robust data and established safety profile of the rVSV platform in general. CEPI’s investment of $3.2 million will be crucial in advancing this candidate. This funding will support the generation of a Master Virus Seed (MVS) stock, a critical early-stage manufacturing step that ensures consistency and scalability, and the subsequent transfer of processes to a contract development and manufacturing organization (CDMO) for Good Manufacturing Practice (GMP) production. GMP compliance is essential for producing clinical-grade doses suitable for human trials, thereby paving the way for eventual human evaluation. The speed at which these initial manufacturing steps can be completed will significantly influence the timeline for moving into Phase 1 clinical trials.
2. Moderna’s mRNA Platform: Leveraging a Pandemic-Proven Technology
Moderna’s BDBV vaccine candidate harnesses the power of messenger RNA (mRNA) technology, the same innovative platform that played a transformative role in the rapid development of highly effective COVID-19 vaccines. The mRNA platform allows for incredibly swift adaptation to new viral threats, as it primarily involves modifying genetic code rather than culturing live viruses. This agility is a significant advantage in responding to fast-moving epidemics.
CEPI is making a substantial investment of up to $50 million in Moderna’s candidate, a sum that will cover preclinical testing, Phase 1 clinical trials, and, critically, simultaneous manufacturing efforts. This "at-risk" manufacturing strategy is a cornerstone of CEPI’s fast-tracking approach, enabling the program to advance immediately into Phase 2 and Phase 3 trials if Phase 1 results prove successful. This parallel processing of development and manufacturing can shave months, or even years, off the traditional vaccine development timeline. Stephane Bancel, CEO of Moderna, reaffirmed the company’s commitment, stating, "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
From Moderna’s perspective, this CEPI investment holds significant strategic value beyond the immediate BDBV outbreak. The company’s financial performance in the wake of the COVID-19 pandemic has seen a recalibration. Fourth-quarter revenue last year was down 30% year-over-year, and the first quarter of 2026 brought in $0.4 billion, with approximately 80% derived from international markets. In 2025, Moderna reported spending $3.1 billion on research and development expenses against a revenue of $1.9 billion. This financial context highlights the commercial risks associated with developing vaccines for rare diseases like BDBV, where the market is limited and the outbreak localized. CEPI’s grant effectively offloads a significant portion of the financial burden for this commercially risky program. In return, Moderna gains the opportunity to further validate its mRNA technology across its "filovirus pipeline" — which includes other Ebolavirus species and Marburg virus — accumulating crucial clinical data and reinforcing the platform’s versatility and rapid response capabilities, all at little financial cost to the company.
Interestingly, this significant investment in mRNA technology by CEPI occurs against a backdrop of shifting national priorities in some countries. In August 2025, the Trump administration notably terminated 22 contracts focused on developing mRNA vaccines and significantly wound down additional federal investments in mRNA technology. This divergence underscores a potential gap in global health preparedness, where international bodies like CEPI are stepping in to ensure critical scientific advancements continue, even if national governments reduce their focus on certain innovative platforms.
3. University of Oxford’s ChAdOx1 Viral Vector Platform: Versatility and Cross-Protection
The University of Oxford’s vaccine candidate is built upon the well-established ChAdOx1 viral vector platform, the same technology that underpinned AstraZeneca’s highly utilized COVID-19 vaccine. This platform uses a replication-deficient chimpanzee adenovirus to deliver genetic material that triggers an immune response. The ChAdOx1 platform has demonstrated its versatility and safety profile in millions of people worldwide.
Crucially, this technology has also shown efficacy against a range of related filoviruses, including the Zaire ebolavirus, Sudan virus, and Marburg virus. This broad-spectrum potential is a significant asset, suggesting that a single platform could be adapted to protect against multiple filoviral threats. CEPI’s investment of $8.6 million in Oxford’s candidate will cover essential steps, including preclinical testing, the creation of a Master Virus Seed stock, and the production of clinical-grade doses necessary for human trials. The proven adaptability of the ChAdOx1 platform positions it as a strong contender in the race against BDBV.
Broader Implications and the Future of Pandemic Preparedness
The fast-tracking of these three diverse vaccine candidates for BDBV highlights several critical aspects of global health security. Firstly, it underscores the persistent and unpredictable nature of emerging infectious diseases, demanding constant vigilance and proactive investment in vaccine R&D. The fact that BDBV has only caused two prior outbreaks, yet now necessitates an emergency response, illustrates the dynamic landscape of viral threats.
Secondly, CEPI’s model of public-private partnership is proving indispensable. By de-risking vaccine development for pathogens with limited commercial appeal, CEPI ensures that scientific innovation is directed towards global health needs, not solely market profitability. This collaborative approach involves not only pharmaceutical companies and academic institutions but also global health organizations like the WHO and Africa CDC, whose epidemiological insights are vital for guiding development priorities.
The announcement also touches upon the crucial aspect of equitable access. As work on these candidates progresses, CEPI is not resting. The organization continues to evaluate additional promising candidates, including through an open call for proposals, ensuring a comprehensive and competitive pipeline. Furthermore, CEPI is actively coordinating with key global health finance institutions such as Gavi, the Vaccine Alliance, the World Bank, and various development finance institutions. This coordination is designed to ensure that "surge financing" is readily available for large-scale procurement and equitable distribution if any of the trials prove successful. This foresight is critical to avoid the vaccine nationalism and access disparities observed during the early phases of the COVID-19 pandemic.
The rapid advancement of these BDBV vaccine candidates is a testament to the accelerated pace of vaccine science, particularly following the innovations spurred by COVID-19. The deployment of mRNA and viral vector technologies, refined through the pandemic, now offers unprecedented speed in responding to novel outbreaks. This multi-platform approach not only increases the chances of finding an effective vaccine for BDBV but also builds a more robust toolkit for future encounters with other emerging pathogens. The challenge remains to navigate the complex pathways of clinical trials, regulatory approval, and manufacturing scale-up, all while the virus continues its relentless spread in the affected communities of the DRC and Uganda. The global community’s ability to respond swiftly and equitably to this BDBV threat will serve as a crucial test of its commitment to global health security.
Leave a Reply